The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia

Vanessa Meier-Stephenson¹,²
Justin Riemer¹,²
Aru Narendran¹–³

¹Department of Oncology, Cumming School of Medicine, University of Calgary, ²Department of Pediatrics, Alberta Children’s Hospital, ³Pediatric Oncology Experimental Therapeutics Investigators Consortium (POeTIC) Laboratory, Calgary, AB, Canada

Purpose: Refractory pediatric leukemia remains one of the leading causes of death in children. Intensification of current chemotherapy regimens to improve the outcome in these children is often limited by the effects of drug resistance and cumulative toxicity. Hence, the search for newer agents and novel therapeutic approaches are urgently needed to formulate the next-generation early-phase clinical trials for these patients.

Materials and methods: A comprehensive library of antimicrobials, including eight HIV protease inhibitors (nelfinavir [NFV], saquinavir, indinavir, ritonavir, amprenavir, atazanavir, lopinavir, and darunavir), was tested against a panel of pediatric leukemia cells by in vitro growth inhibition studies. Detailed target modulation studies were carried out by Western blot analyses. In addition, drug synergy experiments with conventional and novel antitumor agents were completed to identify effective treatment regimens for future clinical trials.

Results: Several of the HIV protease inhibitors showed cytotoxicity at physiologically relevant concentrations (half-maximal inhibitory concentration values ranging from 1–24 µM). In particular, NFV was found to exhibit the most potent antileukemic properties across all cell lines tested. Mechanistic studies show that NFV leads to the induction of autophagy and apoptosis possibly through the induction of endoplasmic reticulum stress. Furthermore, interference with cell signaling pathways, including Akt and mTOR, was also noted. Finally, drug combination studies have identified agents with potential for synergy with NFV in its antileukemic activity. These include JQ1 (BET inhibitor), AT101 (Bcl-2 family inhibitor), and sunitinib (TK inhibitor).

Conclusion: Here, we show data demonstrating the potential of a previously unexplored group of drugs to address an unmet therapeutic need in pediatric oncology. The data presented provide preclinical supportive evidence and rationale for future studies of these agents for refractory leukemia in children.

Keywords: nelfinavir, HIV protease inhibitors, pediatric leukemia, endoplasmic reticulum stress, autophagy, apoptosis

Introduction

Despite the recent advances achieved in the treatment of leukemia in children, the prognosis of relapsed and refractory disease remains dismal with more than 50% mortality rate.¹–³ Acute and long-term toxicities of current chemotherapy agents often limit their further intensification, thus highlighting an urgent need for novel therapeutic approaches to develop newer, safer treatment protocols. One approach to circumvent such toxicity concerns is to consider activity in compounds with previously established clinical data and use, such as that of antimicrobials.
Employing agents from the field of infectious diseases in the fight against cancer has historical precedence, as exemplified by the chemotherapeutic fludarabine, which is a fluorinated nucleotide analog of the antiviral agent vidarabine, or the tetracycline, doxycycline which has shown activity against breast cancer. Here, we bring focus to a class of antivirals – the HIV protease inhibitors (PIs) – which have activity against pediatric leukemia.

The HIV PIs were first developed in the early 1990s, beginning with saquinavir that was rationally designed to fit the HIV aspartyl protease – an enzyme for which there are no human analogs. First approved for use by 1995, the PIs have had over two decades of clinical use in the treatment regimens of HIV patients, including use in children. In HIV patients on PI-based therapy, it was noted that there was a dramatic drop in the rates of HIV-associated malignancies, unrelated to the viral loads or CD4 counts. This had led to studies that evaluated the effects of PIs in cancer therapy. Some of the earlier studies included murine xenograft models of Kaposi’s sarcoma, whereby Sgadari and colleagues demonstrated several PIs had effects on tumor growth, invasion, angiogenesis, and survival. Ikzoe et al pursued the PIs’ application to multiple myeloma, demonstrating effects on cell cycle arrest and STAT3 and ERK signaling. By the early 2000s, PIs have been shown to have activity in vitro against a number of adult solid tumors, the results of which are reported in a landmark paper by Gills et al. Here, a 60-cell line panel of malignancies, including breast, colon, lung, renal, leukemia, and melanoma, were treated with nelfinavir (NFV) to reveal growth inhibition at ranges between $10^{-5}$ and $10^{-6}$ M. Additionally, they confirm cytotoxicity via apoptosis and provide evidence for mechanisms of endoplasmic reticulum (ER) stress and autophagy.

Supported by the findings from these studies, a number of clinical trials have been conducted, with promising early results (Table S1). For example, in treatment-resistant multiple myeloma, a phase I clinical trial of NFV with bortezomib showed partial response in one-third of patients, as well as safety and tolerability of NFV at doses used. Similarly, in a phase I trial of advanced stage non-small-cell lung cancer, NFV given in combination with radiation resulted in complete response in five of nine patients and partial response in the remaining four patients. Again, for a phase I trial in pancreatic cancer, NFV with radiation showed partial computed tomography (CT) responses in five of ten patients with a substantial reduction in tumor size atypical for radiation treatment alone. Finally, a phase I clinical trial of NFV against various adult solid tumors also showed partial responses in up to 3 of 11 of evaluable patients with drug safety and tolerability. Additionally, there is some preclinical work on PI-derivatives showing promising results, including in leukemia.

Despite the early promising data obtained from adult cancer studies, however, specific investigations directed against pediatric malignancies so far have not been reported. The present study describes the identification NFV-mediated cytotoxicity in pediatric leukemia cells and evaluation of mechanisms involved in this process. We also provide information on agents with potential for effective drug combination for evaluation in future treatment protocols.

**Material and methods**

**Cell lines and cell culture**

Cell lines used were SEM, C1, Molt3, TIB202, Molm13, and MV4-11, purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and are previously described. Additionally, the cell line Poetic2.2 was also employed – a line developed in our laboratory derived from a 13-year-old pre-B acute lymphoblastic leukemia patient with a p16 deletion (Conjoint Health Research Ethics Board [CHREB] number: HREBA.CC-16-0286). Cells were maintained in Opti-MEM media (Gibco, Invitrogen Corporation, Burlington, ON, Canada) supplemented with 10% heat-inactivated fetal bovine serum, 100 units/mL of penicillin, and 100 µg/mL of streptomycin (Gibco) and incubated in a humidified 5% CO2 incubator. Cells were passaged approximately every 3–5 days, by centrifuging the suspension and resuspending the pellet in fresh media. Primary leukemic cells were obtained after ethics board approval (CHREB number: HREBA.CC-16-0286) and written informed consent from the parent or guardian. Normal lymphocytes were obtained from healthy volunteers after receipt of their verbal consent. Lymphocytes were isolated by density gradient centrifugation using Ficoll-Paque Plus (GE Healthcare Life Sciences, Mississauga, ON, Canada).

**Materials and reagents**

The antimicrobial library, consisting of 112 compounds (68 antibacterials; 39 antivirals; and five other) was purchased from Selleck Chemicals (Burlington, ON, Canada) and contained the PIs, NFV, indinavir, amprenavir, and atazanavir. Additional PIs – lopinavir, ritonavir, darunavir (DRV), and saquinavir were purchased from Sigma-Aldrich (St Louis, MO, USA). Compounds were dissolved in dimethylsulfoxide (DMSO) to a stock concentration of 10 mM. Subsequent dilutions were made using cell culture media, as needed, to gain concentrations of 40 to $10^{-6}$ M.
In vitro cytotoxicity assays

For the antimicrobial library screening, three cell lines were used in the testing, C1, Molt3, and Poetic2.2. Cells were passaged during exponential growth and seeded in 96-well plates (Grenier BioOne, Monroe, NC, USA) at 5×10^3 cells per well. Using four antimicrobial drug dilutions (0.01, 0.1, 1, and 10 µM) and the corresponding DMSO vehicle control, the drugs were added to the plates and incubated. After 4 days, cell viability was quantified using Alamar blue assay (Invitrogen, Burlington, ON, Canada) and cytotoxicity curves created. For the more detailed cytotoxicity curves, a larger dilution series was employed, and calculation of the half- and quarter-maximal inhibitory concentrations (IC_{50} and IC_{25}, respectively) were determined for each drug based on independent cytotoxicity plots.

Drug combination studies

Pediatric leukemia cells were cultured as described above. SEM and Molm13 cell lines were selected as representative cell lines for the set and underwent the initial synergism screen against 35 chemotherapeutic agents, both conventional and novel. For the drug combination studies, the chemotherapy agents were first plated at 1 and 0.1 µM concentrations in triplicate wells of 96-well plates. NFV was added to each according to predetermined IC_{50} values. Cells were then plated at 5×10^3 cells/well. After 4 days of incubation, cell survival was quantified as above. Agents with the highest activity (ie, lowest IC_{50}) in combination with NFV were selected for more detailed analyses against all seven cell lines to confirm the consistency of the findings across the broader panel. Various concentrations, ranging from 10 to 10^8 µM, were added to the wells alone or in combination with the corresponding IC_{50} of NFV for that cell line. Cell numbers and viability were determined after 4 days. The combination indices (CIs) were determined as previously described, where a CI <1 indicates synergy between the agents, CI =1 indicates that the agents are working additively, and CI >1 indicates that the agents are antagonistic.

Target modulation analyses

Target modulation by PIs was determined by Western blot analyses. Briefly, cells were incubated with the PI or appropriate control for 6, 12, or 24 h, as indicated, then lysed using radioimmunoprecipitation assay-based lysis buffer containing phosphatase and PIs. Lysates were resolved and transferred electrophoretically, and then probed using specific antibodies (Cell Signaling, Danvers, MA, USA; EMD Millipore, Billerica, MA, USA; and AbCam, Cambridge, UK).

Results

PIs show potential as antileukemics

Testing of the antimicrobial library against a panel of leukemia cell lines revealed several compounds with cytotoxic effects (data not shown), including several drugs from the antiviral class, the HIV PIs. As a group, these agents showed a class-effect cytotoxicity at the upper 10 µM concentration of the screen, reaching IC_{20-25} for NFV, ritonavir, and lopinavir. This provided the initial suggestion to further investigate this class of agents.

PIs as a class are cytotoxic to leukemia

Extending the findings from the initial screen, eight different US Food and Drug Administration-approved PIs were tested for cytotoxicity against the seven pediatric leukemia cell lines. Their IC_{50} values are reported in Table 1 and range from 1 to >40 µM. As a comparator for clinically relevant plasma levels, the table also includes the typical drug levels obtained from HIV dosing regimens for each of the corresponding PIs. Boxes have been color-coded according to presumed feasibility of achieving that level in the plasma based on current HIV dosing regimens. Overall, the PIs with the most consistent activity across cell lines was NFV. Lopinavir, ritonavir, and saquinavir also showed activity against many of the cell lines tested.

NFV shows selective targeting of leukemic cells

Given the findings from the class analyses, NFV was selected for more detailed cytotoxicity assays. Assessment of activity against seven cell lines gave IC_{50}s ranging from 1 to 24 µM (Figure 1A). To determine the degree of selectivity of NFV toward leukemia cells, two populations of normal lymphocytes from healthy volunteers were also screened and showed minimal cytotoxicity at the upper concentrations tested (Figure 1A). Efficacy against primary leukemic cells was also demonstrated, showing analogous cytotoxicity curves with IC_{50} ranging from 16–20 µM (Figure 1B).

NFV induces ER stress, leading to autophagy and apoptosis

To delineate the underlying mechanisms of NFV on leukemia, we selected two of the above cell lines, SEM (an ALL cell line) and Molm13 (an AML cell line). Here,
we show that treatment of these cells with NFV induces ER stress in the cell, as shown by elevated levels of the phosphorylated ER stress marker, eIF2α – a protein subunit that controls the initiation of mRNA translation. In its phosphorylated form, P-eIF2α prevents the further translation of proteins, reducing the ER workload in an attempt to allow the cell to recover.  

When cells are treated with NFV, a concentration- and time-dependent increase in this marker was observed (Figure 2). Also, there is simultaneous elevation of a downstream marker, CHOP, and an additional stress signaling marker, ATF3. This added cellular stress may subsequently induce the processes of autophagy and apoptosis (Figure 3). Immunoblots of autophagy markers show relatively stable levels of Beclin-1 and LC3B, in the treated and untreated cells (Figure 3C and F), consistent with the complexity and specificity of measuring autophagy in such systems.  

We thus show additional support of the cells’ reliance on this pathway through the use of autophagy inhibitors, 3-methyladenine and thapsigargin, which result in significant increase in cell death when the cell cannot  

### Table 1 Summary of IC_{50} values (µM) for eight FDA-approved HIV-protease inhibitors tested against seven different pediatric leukemia cell lines

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Amprenavir</th>
<th>Atazanavir</th>
<th>Darunavir</th>
<th>Indinavir</th>
<th>Lopinavir</th>
<th>NFV</th>
<th>Ritonavir</th>
<th>Saquinavir</th>
<th>Cell line comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEM</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>17</td>
<td>17.4±5.8</td>
<td>17.5</td>
<td>28</td>
</tr>
<tr>
<td>C1</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>17</td>
<td>13.8±0.4</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>pre-B ALL</td>
</tr>
<tr>
<td>Molt3</td>
<td>&gt;40</td>
<td>24</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>35</td>
<td>16±1.4</td>
<td>&gt;40</td>
<td>30</td>
<td>T-ALL</td>
</tr>
<tr>
<td>Poetic2.2</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>23</td>
<td>13.3±0.4</td>
<td>35</td>
<td>&gt;40</td>
<td>ALL; p6 deletion on relapse</td>
</tr>
<tr>
<td>MV4-11</td>
<td>&gt;40</td>
<td>8</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>4</td>
<td>8.7±5.9</td>
<td>6.5</td>
<td>27</td>
<td>Biphenotypic B myelomonocytic leukemia; ITD of FLT3</td>
</tr>
<tr>
<td>Molm13</td>
<td>&gt;40</td>
<td>7.5</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>1</td>
<td>8.2±7.0</td>
<td>4.5</td>
<td>6.5</td>
<td>AML FAB M5a; ITD of FLT3</td>
</tr>
<tr>
<td>TIB202</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>&gt;40</td>
<td>15.0±0.7</td>
<td>&gt;40</td>
<td>30</td>
<td>AML; MLL-AF9 fusion gene</td>
</tr>
<tr>
<td>Plasma level*</td>
<td>5–15 µM</td>
<td>0.4–1 µM</td>
<td>10–20 µM</td>
<td>8–20 µM</td>
<td>5–20 µM</td>
<td>6–10 µM</td>
<td>7–11 µM</td>
<td>1–4 µM</td>
<td></td>
</tr>
</tbody>
</table>

Notes:  
*Per standard HIV dosing regimen. IC_{50} values achievable in the plasma via current HIV dosing regimens are highlighted in green; possibly achievable are in yellow; and less likely achievable are in red.  
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; FDA, US Food and Drug Administration; IC_{50}, half-maximal inhibitory concentration; ITD, internal tandem deletion; NFV, nelfinavir.

Figure 1 (A) Cytotoxicity assays of NFV against seven pediatric leukemia cell lines. Normal lymphocyte cytotoxicity is included for control. For the cell lines, plots are representative of at least triplicate independent experiments. (B) Cytotoxicity of NFV against primary leukemia cells.  
Abbreviations: DMSO, dimethylsulfoxide; NFV, nelfinavir.
Figure 2. ER stress induced in NFV-treated and untreated cells.

Notes: Immunoblots of (A) time-dependent and (B) concentration-dependent effects. DRV has been included as a negative control, as it was found to be inactive at doses tested in the cytotoxicity assays. Then, upper incubation for each of the lysates employed above was 24 hour for SEM, and 12 hour for Molm13.

Abbreviations: Conc, concentration; DMSO, dimethylsulfoxide; DRV, darunavir; ER, endoplasmic reticulum; NFV, nelfinavir.

Figure 3 (Continued)
Abbreviations: (concentrations determined per results of prior cytotoxicity and time assays).

Note:

Figure 3 (Figure 3).

Figure 4 (Figure 4).

Figure 3 Autophagy and apoptosis in NFV-treated and untreated cells.

Notes: Immunoblots of (A) time-dependent and (B) concentration-dependent effects. The Molm13 cell line was treated with an upper concentration of 20 µM NFV, while the SEM line was treated with 40 µM (per results of prior cytotoxicity assays). Autophagy in SEM treated with nelfinavir (C) and effects of cell survival with NFV alone and in combination with two different autophagy inhibitors, 3-methyladenine (D) and thapsigargin (E) treated for 96 h. Autophagy in Molm13 treated with nelfinavir for 12 h (F) and effects of cell survival with NFV alone and in combination with two different autophagy inhibitors, 3-methyladenine (G) and thapsigargin (H) treated for 48 h.

Abbreviations: 3-MA, 3-methyladenine; DMSO, dimethylsulfoxide; DRV, darunavir; NFV, nelfinavir; Thapsi, thapsigargin.

NFV activity shows synergy with specific antileukemic agents

To determine which drugs NFV could be combined with to provide enhanced antileukemic activity, the SEM and Molm13 cell lines were screened against a panel of 35 different chemotherapy agents, both novel and conventional, with diverse mechanisms of action. The drug panel was screened alone and in combination with NFV at two different concentrations, 1 µM and 0.1 µM (Figures 5 and S1). Based on these results, compounds that showed more than an additive change in cytotoxicity when combined were selected for more detailed studies to assess synergy and determine CIs. Agents selected were JQ1 (BET inhibitor), AT101 (Bcl-2 family inhibitor), and Sunitinib (TK inhibitor). CIs when tested across the panel of leukemia cell lines ranged from 0.07 to 0.95 for JQ1; 0.05–1.8 for AT101; and 0.013–0.6 for Sunitinib, implying synergistic effects across most cell lines (Figure 6; Table 2).

Discussion

The acute and long-term toxicities of chemotherapy regimens used to treat refractory and relapsed pediatric leukemia have prompted the search for newer, safer agents. Here, through a search of antimicrobials, we identify the HIV PIs, with their decades of use and availability of pharmacokinetic and toxicity data, as potential candidates for the safe combination and incorporation into chemotherapy regimens.

The PIs have only just begun to be noticed for their anticancer properties with preliminary associations made in HIV patients with malignancies. NFV, in particular, has received the most attention with preliminary studies emerging in numerous adult malignancies, including castration-resistant prostate cancer, rectal cancer,
Nelfinavir targets pediatric leukemia, pancreatic cancer, breast cancer, and lung cancer (Table S1). Though never before reported in pediatric cancers, our current work on pediatric leukemias suggest that NFV would also have significant antileukemic properties, with IC_{50} ranging from 1 to 15 μM – concentrations that are physiologically obtainable based on current oral HIV dosing regimens.\(^25,26\)

The mechanism by which NFV exerts its effects appears to involve the induction of ER stress (Figure 2), which may drive the cell toward autophagy and ultimately, apoptosis (Figure 3). A similar mechanism has been shown in some adult cancers in vitro where NFV has been shown to induce ER stress in head and neck, breast, and prostate cancer cells.\(^37-39\) The autophagy induction is further characterized by the application of autophagy inhibitors, 3-methyladenine and thapsigargin, which greatly reduce cell survival when combined with NFV (Figure 3C–H). This is consistent with previous findings where, when similar inhibitors resulted in lethal or near-lethal cellular toxicity.\(^40\) When the cancer cells’ homeostatic mechanisms are overwhelmed, cells undergo apoptosis. Here, we also show elevated levels of apoptosis markers, including cleaved PARP and caspase-9, in response to NFV treatment, supporting this mechanism of cell death (Figure 3B).

NFV also acts by targeting crucial cell-signaling pathways, such as Akt and mTOR.\(^40\) Here, we show that these mechanisms are present in its effect in pediatric leukemia cells, showing both time- and concentration-dependent effects on cell signaling (Figure 4). Again, such signaling pathways are highlighted as a key target and one of

**Figure 5** Combination studies with known chemotherapy regimens in SEM.

**Notes:** Drugs were plated in 96-well plates alone and in combination with the IC_{50} of NFV, determined from the corresponding cell line cytotoxicity screens. (A) Plated drugs at 1 μM final concentration; (B) drugs at 0.1 μM. The cells were then added to each (5,000 cells/well) and incubated for four days before being read by Alamar blue assay. The control (DMSO) and NFV alone are shown with patterned bars.

**Abbreviations:** DMSO, dimethylsulfoxide; IC_{50}, quarter-maximal inhibitory concentration; NFV, nelfinavir.
the hallmarks in cancer. Interestingly, it is this off-target effect on mTOR that has also been shown to play a role in the treatment of HIV infection. Additional pathways implicated in the literature with NFV include oxidative stress mechanisms, decreased angiogenesis, and cell cycle arrest.

In future clinical trials, the inclusion of NFV in combination, rather than as a single agent, would provide additional benefits.
with enhanced tumor killing, reduction of chemotherapy-specific toxicities, and, ideally, avoidance of therapy resistance. NFV has already been considered in combination with other chemotherapy agents in clinical trials, including with doxorubicin for breast cancer and with bortezomib for myeloma. For both cases, NFV was able to act synergistically with the standard therapeutics to overcome drug resistance. In the former case, NFV was able to enhance the effects of doxorubicin against a multidrug-resistant breast cancer cell line (MCF-7/Dox), considered to be multifactorial and involving suppression of P-gp-mediated drug efflux, inhibition of Akt activation, and induction ER stress, leading to autophagy.

Similarly, in the case of myeloma, NFV was able to enhance bortezomib to overcome both bortezomib and carfilzomib resistance, again, attributed to ER stress leading to increased unfolded protein response (UPR) pathway-induced apoptosis. Additionally, owing to its influence on cellular stress, NFV has also been considered in combination with other agents in preclinical studies.

Table 2 Combination indices of nelfinavir in combination with JQ1, AT101, and Sunitinib

<table>
<thead>
<tr>
<th>Cell line</th>
<th>JQ1</th>
<th>AT101</th>
<th>Sunitinib</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEM</td>
<td>0.18</td>
<td>0.17</td>
<td>0.60</td>
</tr>
<tr>
<td>Molm13</td>
<td>0.18</td>
<td>0.056</td>
<td>0.34</td>
</tr>
<tr>
<td>CI</td>
<td>0.2</td>
<td>0.70</td>
<td>0.065</td>
</tr>
<tr>
<td>Mol3</td>
<td>0.97</td>
<td>1.2</td>
<td>0.37</td>
</tr>
<tr>
<td>Poetic2.2</td>
<td>0.73</td>
<td>1.8</td>
<td>1.2</td>
</tr>
<tr>
<td>MV4-11</td>
<td>0.11</td>
<td>0.12</td>
<td>0.065</td>
</tr>
<tr>
<td>TiB202</td>
<td>0.071</td>
<td>0.11</td>
<td>0.013</td>
</tr>
</tbody>
</table>

Figure 6 Combination studies of NFV with JQ1, Sunitinib, and AT101.

Notes: Drugs were plated in 96-well plates alone and in combination with NFV. The drug in question had dilutions ranging from 0.001 to 10 µM, while NFV was held constant at the cell line’s IC_{50} for NFV. The cells were then added to each (5,000 cells/well) and incubated for four days before being read by Alamar blue assay. Abbreviations: DMSO, dimethylsulfoxide; IC_{50}, quarter-maximal inhibitory concentration; NFV, nelfinavir.
considered in combination with radiation therapy.\textsuperscript{33,39,47,48}

To consider NFV’s application in the treatment of pediatric leukemia, we examined a panel of mechanistically diverse chemotherapeutic drugs in combination with NFV. This screen revealed synergy with the BET inhibitor, JQ1, with CIs ranging from 0.07 to 0.97. Based on the evidence of NFV’s influence on cellular stress and signaling targets, synergy with agents that alter epigenetic processes may be postulated. Indeed, there is evidence of synergy in literature of epigenetic drugs with both ER stress inducers and mTOR inhibitors.\textsuperscript{49–51} Similarly, for other pathways revealed, the Bcl-2 family inhibitor, AT101, and the TK inhibitor, Sunitinib, synergy with drugs that induce ER stress have been shown previously.\textsuperscript{36,52} For these combinations, in our studies, CIs ranged from 0.05 to 1.8 and 0.013 to 0.6, respectively, providing evidence for their use together.

**Conclusion**

Pediatric leukemia remains a critical area for ongoing research as our current therapies remain toxic to healthy cells and relapses of chemoresistant-disease continue to occur at unacceptable rates. Here we show that HIV PIs, namely NFV, that has been employed for decades against the HIV virus in both adults and children, has selective anticancer effects with a therapeutic window compared to normal lymphocytes. We have also identified the potential mechanisms behind this observation. Finally, we show that the drug is able to act synergistically with certain currently approved antileukemic agents providing the framework to design of a future in vivo studies and subsequently early-phase clinical trials for refractory leukemia in children.

**Acknowledgments**

This study was supported in part by the POETIC Foundation, Alberta Children’s Hospital Foundation, and the Kids Cancer Care Foundation of Alberta (KCCFA).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


## Supplementary materials

### Table S1 Summary of clinical trials involving NFV to date (as per the NCI Clinical Trials Database)

<table>
<thead>
<tr>
<th>Protocol</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT 0145106</td>
<td>Solid tumors: A phase I trial of NFV (viracept) in adults with solid tumors</td>
</tr>
<tr>
<td>NCT 00436735</td>
<td>Solid tumors: NFV in treating patients with metastatic, refractory, or recurrent solid tumors</td>
</tr>
<tr>
<td>NCT 00589056</td>
<td>NSCLC: NFV, radiation therapy, cisplatin, and etoposide in treating patients with stage III non-small-cell lung cancer that cannot be removed by surgery</td>
</tr>
<tr>
<td>NCT 01068327</td>
<td>Pancreatic cancer: stereotactic radiation therapy, NFV mesylate, gemcitabine hydrochloride, leucovorin calcium, and fluorouracil in treating patients with locally advanced pancreatic cancer</td>
</tr>
<tr>
<td>NCT 01925378</td>
<td>Cervical intraepithelial neoplasia: a phase II single-arm intervention trial of NFV in patients with grade 2/3 or 3 cervical intraepithelial neoplasia</td>
</tr>
<tr>
<td>NCT 01959672</td>
<td>Pancreatic cancer: NFV mesylate in treating patients with locally advanced pancreatic cancer</td>
</tr>
<tr>
<td>NCT 01079286</td>
<td>Renal cell cancer: study of NFV and temsirolimus in patients with advanced cancers</td>
</tr>
<tr>
<td>NCT 00704600</td>
<td>Rectal cancer: NFV, a phase II/phase II rectal cancer study</td>
</tr>
<tr>
<td>NCT 01065844</td>
<td>Adenoid cystic cancer: NFV in recurrent adenoid cystic cancer of the head and neck</td>
</tr>
<tr>
<td>NCT 01164709</td>
<td>Hematologic cancer: NFV mesylate and bortezomib in treating patients with relapsed or progressive advanced hematologic cancer</td>
</tr>
<tr>
<td>NCT 01086332</td>
<td>Pancreatic cancer: evaluation of NFV and chemoradiation for pancreatic cancer</td>
</tr>
<tr>
<td>NCT 01485731</td>
<td>Cervical cancer: safety study of NFV + cisplatin + pelvic radiation therapy to treat cervical cancer</td>
</tr>
<tr>
<td>NCT 02024009</td>
<td>Pancreatic cancer: systemic therapy and chemoradiation in advanced localized pancreatic cancer: 2</td>
</tr>
<tr>
<td>NCT 00915694</td>
<td>Glioblastoma: NFV, radiation therapy, and temozolomide in treating patients with glioblastoma multiforme</td>
</tr>
<tr>
<td>NCT 01108666</td>
<td>Non-small-cell lung cancer: proton beam radiation with concurrent chemotherapy and NFV for inoperable stage III non-small-cell lung cancer</td>
</tr>
<tr>
<td>NCT 00791336</td>
<td>Study to evaluate using NFV with chemoradiation for non-small-cell lung cancer</td>
</tr>
<tr>
<td>NCT 02207439</td>
<td>Larynx carcinoma: A phase II of NFV, given with definitive, concurrent chemoradiotherapy in patients with locally advanced, human papilloma virus-negative, squamous cell carcinoma larynx</td>
</tr>
<tr>
<td>NCT 01020929</td>
<td>Glioma: NFV and concurrent radiation and temozolomide in patients with WHO grade IV glioma</td>
</tr>
<tr>
<td>NCT 01535281</td>
<td>Myeloma: NFV and lenalidomide/dexamethasone in patients with progressive multiple myeloma that have failed lenalidomide-containing therapy</td>
</tr>
<tr>
<td>NCT 01728779</td>
<td>Metastatic lesions of the lung, liver, or bone: stereotactic body radiation with NFV for oligometastases</td>
</tr>
<tr>
<td>NCT 00233948</td>
<td>Liposarcoma: NFV mesylate in treating patients with recurrent, metastatic, or unresectable liposarcoma</td>
</tr>
<tr>
<td>NCT 02188537</td>
<td>Myeloma: NFV as bortezomib-sensitizing drug in patients with proteasome inhibitor nonresponsive myeloma</td>
</tr>
<tr>
<td>EudraCT#:</td>
<td>Pancratic cancer: a phase II study in patients with locally advanced pancreatic carcinoma: ARC-II – Akt-inhibition by NFV plus chemoradiation with gemcitabine and cisplatin</td>
</tr>
<tr>
<td>2008-006302-42</td>
<td>University of Oxford</td>
</tr>
</tbody>
</table>

**Abbreviations:** EBV, Ebstein-Barr virus; NCI, National Cancer Institute; NFV, nelfinavir; NSCLC, non-small-cell lung cancer; WHO, World Health Organization.
Figure S1 Combination studies with known chemotherapy regimens in Molm13.

Notes: Drugs were plated in 96-well plates alone and in combination with the IC_{50} of NFV, determined from the corresponding cell line cytotoxicity screens. (A) Plated drugs at 1 µM final concentration; (B) drugs at 0.1 µM. The cells were then added to each (5,000 cells/well) and incubated for four days before being read by Alamar blue assay. The control (DMSO) and NFV alone are shown with patterned bars.

Abbreviations: DMSO, dimethylsulfoxide; IC_{50}, half-maximal inhibitory concentration; NFV, nelfinavir.